The impact of in silico screening in the discovery of novel and safer drug candidates

Pharmacology and Therapeutics

Volumn 175, Issue , 2017, Pages 47-66

  Rognan, Didier ^a  

^a Faculté de Pharmacie   (France)

Author keywords

Hit; Pharmacokinetics; Profile; Safety; Screening; Target

Indexed keywords

LIGAND; NEW DRUG; PROTEIN;

COMPUTER AIDED DESIGN; COMPUTER MODEL; DATA ANALYSIS; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; PHARMACODYNAMICS; PHARMACOPHORE; PHYSICAL CHEMISTRY; POLYPHARMACOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; STATIC ELECTRICITY; COMPUTER SIMULATION; DRUG DEVELOPMENT; PHARMACOKINETICS; PHARMACOLOGY;

COMPUTER SIMULATION; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHARMACOKINETICS; PHARMACOLOGICAL AND TOXICOLOGICAL PHENOMENA;

EID: 85013656808     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.02.034     Document Type: Review

References (197)

1. Alex, A.A., Millan, D.S., Contribution of structure-based drug design tothe discovery of marketed drugs. Livingstone, D.J., Davis, A.M., (eds.) Drug design strategies: Quantitative approaches, 2012, RSC Publishing, 108–150.
2. Aliagas, I., Gobbi, A., Heffron, T., Lee, M.-L., Ortwine, D.F., Zak, M., Khojasteh, S.C., A probabilistic method to report predictions from a human liver microsomes stability QSAR model: A practical tool for drug discovery. Journal of Computer-Aided Molecular Design 29 (2015), 327–338.
3. Altman, R.B., PharmGKB: A logical home for knowledge relating genotype to drug response phenotype. Nature Genetics, 39, 2007, 426-426.
4. Anighoro, A., Bajorath, J., Three-dimensional similarity in molecular docking: Prioritizing ligand poses on the basis of experimental binding modes. Journal of Chemical Information and Modeling, 2016.
5. Babine, R.E., Bleckman, T.M., Kissinger, C.R., Showalter, R., Pelletier, L.A., Lewis, C.,.. Villafranca, J.E., Design, synthesis and X-ray crystallographic studies of novel FKBP-12 ligands. Bioorganic & Medicinal Chemistry Letters 5 (1995), 1719–1724.
6. Baell, J., Walters, M.A., Chemistry: Chemical con artists foil drug discovery. Nature 513 (2014), 481–483.
7. Bakheet, T.M., Doig, A.J., Properties and identification of human protein drug targets. Bioinformatics 25 (2009), 451–457.
8. Ballester, P.J., Schreyer, A., Blundell, T.L., Does a more precise chemical description of protein-ligand complexes lead to more accurate prediction of binding affinity?. Journal of Chemical Information and Modeling 54 (2014), 944–955.
9. Bembenek, S.D., Tounge, B.A., Reynolds, C.H., Ligand efficiency and fragment-based drug discovery. Drug Discovery Today 14 (2009), 278–283.
10. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H.,.. Bourne, P.E., The Protein Data Bank. Nucleic Acids Research 28 (2000), 235–242.
11. Besnard, J., Ruda, G.F., Setola, V., Abecassis, K., Rodriguiz, R.M., Huang, X.P.,.. Hopkins, A.L., Automated design of ligands to polypharmacological profiles. Nature 492 (2012), 215–220.
12. Bickerton, G.R., Paolini, G.V., Besnard, J., Muresan, S., Hopkins, A.L., Quantifying the chemical beauty of drugs. Nature Chemistry 4 (2012), 90–98.
13. Bohm, H.J., LUDI: Rule-based automatic design of new substituents for enzyme inhibitor leads. Journal of Computer-Aided Molecular Design 6 (1992), 593–606.
14. Borrel, A., Regad, L., Xhaard, H., Petitjean, M., Camproux, A.C., PockDrug: A model for predicting pocket druggability that overcomes pocket estimation uncertainties. Journal of Chemical Information and Modeling 55 (2015), 882–895.
15. Bowes, J., Brown, A.J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., Whitebread, S., Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. Nature Reviews. Drug Discovery 11 (2012), 909–922.
16. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J., Bork, P., Drug target identification using side-effect similarity. Science 321 (2008), 263–266.
17. Chalopin, M., Tesse, A., Martinez, M.C., Rognan, D., Arnal, J.F., Andriantsitohaina, R., Estrogen receptor alpha as a key target of red wine polyphenols action on the endothelium. PloS One, 5, 2010, e8554.
18. Chen, J.M., Xu, S.L., Wawrzak, Z., Basarab, G.S., Jordan, D.B., Structure-based design of potent inhibitors of scytalone dehydratase: Displacement of a water molecule from the active site. Biochemistry 37 (1998), 17735–17744.
19. Cheng, A.C., Coleman, R.G., Smyth, K.T., Cao, Q., Soulard, P., Caffrey, D.R.,.. Huang, E.S., Structure-based maximal affinity model predicts small-molecule druggability. Nature Biotechnology 25 (2007), 71–75.
20. Cheng, F., Li, W., Wang, X., Zhou, Y., Wu, Z., Shen, J., Tang, Y., Adverse drug events: Database construction and in silico prediction. Journal of Chemical Information and Modeling 53 (2013), 744–752.
21. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., Pangalos, M.N., Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nature Reviews. Drug Discovery 13 (2014), 419–431.
22. Cortes-Ciriano, I., Ain, Q., Subramanian, V., Lenselink, E.B., Mendez-Lucio, O., Ijzerman, A.P.,.. Bender, A., Polypharmacology modelling using proteochemometrics (PCM): Recent methodological developments, applications to target families, and future prospects. Medicinal Chemistry Communications 6 (2015), 24–50.
23. Craig, J.C., Duncan, I.B., Hockley, D., Grief, C., Roberts, N.A., Mills, J.S., Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Research 16 (1991), 295–305.
24. Cushman, D.W., Cheung, H.S., Sabo, E.F., Ondetti, M.A., Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16 (1977), 5484–5491.
25. de Bethune, M.P., Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009). Antiviral Research 85 (2010), 75–90.
26. de Graaf, C., Kooistra, A.J., Vischer, H.F., Katritch, V., Kuijer, M., Shiroishi, M.,.. Leurs, R., Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. Journal of Medicinal Chemistry 54 (2011), 8195–8206.
27. de Graaf, C., Rein, C., Piwnica, D., Giordanetto, F., Rognan, D., Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem 6 (2011), 2159–2169.
28. Deng, Z., Chuaqui, C., Singh, J., Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional protein-ligand binding interactions. Journal of Medicinal Chemistry 47 (2004), 337–344.
29. Desaphy, J., Azdimousa, K., Kellenberger, E., Rognan, D., Comparison and druggability prediction of protein-ligand binding sites from pharmacophore-annotated cavity shapes. Journal of Chemical Information and Modeling 52 (2012), 2287–2299.
30. Diller, D.J., Connell, N.D., Welsh, W.J., Avalanche for shape and feature-based virtual screening with 3D alignment. Journal of Computer-Aided Molecular Design 29 (2015), 1015–1024.
31. DiMasi, J.A., Grabowski, H.G., Hansen, R.W., Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 47 (2016), 20–33.
32. Durrant, J.D., Amaro, R.E., Xie, L., Urbaniak, M.D., Ferguson, M.A., Haapalainen, A.,.. McCammon, J.A., A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Computational Biology, 6, 2010, e1000648.
33. Edfeldt, F.N., Folmer, R.H., Breeze, A.L., Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discovery Today 16 (2011), 284–287.
34. Ehrt, C., Brinkjost, T., Koch, O., Impact of binding site comparisons on medicinal chemistry and rational molecular design. Journal of Medicinal Chemistry 59 (2016), 4121–4151.
35. Ekins, S., Williams, A.J., Krasowski, M.D., Freundlich, J.S., In silico repositioning of approved drugs for rare and neglected diseases. Drug Discovery Today 16 (2011), 298–310.
36. Fishburn, C.S., Attenuating attrition. SciBX, 6, 2013.
37. Fishburn, C.S., Translational research: The changing landscape of drug discovery. Drug Discovery Today 18 (2013), 487–494.
38. Flohr, S., Kurz, M., Kostenis, E., Brkovich, A., Fournier, A., Klabunde, T., Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. Journal of Medicinal Chemistry 45 (2002), 1799–1805.
39. Fourches, D., Muratov, E., Tropsha, A., Trust, but verify: On the importance of chemical structure curation in cheminformatics and QSAR modeling research. Journal of Chemical Information and Modeling 50 (2010), 1189–1204.
40. Fraczkiewicz, R., Lobell, M., Goller, A.H., Krenz, U., Schoenneis, R., Clark, R.D., Hillisch, A., Best of both worlds: Combining pharma data and state of the art modeling technology to improve in silico pKa prediction. Journal of Chemical Information and Modeling 55 (2015), 389–397.
41. Gabel, J., Desaphy, J., Rognan, D., Beware of machine learning-based scoring functions-on the danger of developing black boxes. Journal of Chemical Information and Modeling 54 (2014), 2807–2815.
42. Gao, M., Skolnick, J., The distribution of ligand-binding pockets around protein-protein interfaces suggests a general mechanism for pocket formation. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 3784–3789.
43. Gao, C., Thorsteinson, N., Watson, I., Wang, J., Vieth, M., Knowledge-based strategy to improve ligand pose prediction accuracy for lead optimization. Journal of Chemical Information and Modeling 55 (2015), 1460–1468.
44. Garreau de Loubresse, N., Prokhorova, I., Holtkamp, W., Rodnina, M.V., Yusupova, G., Yusupov, M., Structural basis for the inhibition of the eukaryotic ribosome. Nature 513 (2014), 517–522.
45. Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A.,.. Overington, J.P., ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Research 40 (2012), D1100–D1107.
46. Ghafourian, T., Amin, Z., QSAR models for the prediction of plasma protein binding. BioImpacts: BI 3 (2013), 21–27.
47. Ghosh, E., Kumari, P., Jaiman, D., Shukla, A.K., Methodological advances: The unsung heroes of the GPCR structural revolution. Nature Reviews. Molecular Cell Biology 16 (2015), 69–81.
48. Green, D.V., Leach, A.R., Head, M.S., Computer-aided molecular design under the SWOTlight. Journal of Computer-Aided Molecular Design 26 (2012), 51–56.
49. Greer, J., Erickson, J.W., Baldwin, J.J., Varney, M.D., Application of the three-dimensional structures of protein target molecules in structure-based drug design. Journal of Medicinal Chemistry 37 (1994), 1035–1054.
50. Grosdidier, A., Zoete, V., Michielin, O., Blind docking of 260 protein-ligand complexes with EADock 2.0. Journal of Computational Chemistry 30 (2009), 2021–2030.
51. Hann, M.M., Keseru, G.M., Finding the sweet spot: The role of nature and nurture in medicinal chemistry. Nature Reviews. Drug Discovery 11 (2012), 355–365.
52. Hartenfeller, M., Eberle, M., Meier, P., Nieto-Oberhuber, C., Altmann, K.H., Schneider, G.,.. Renner, S., A collection of robust organic synthesis reactions for in silico molecule design. Journal of Chemical Information and Modeling 51 (2011), 3093–3098.
53. Hartenfeller, M., Zettl, H., Walter, M., Rupp, M., Reisen, F., Proschak, E.,.. Schneider, G., DOGS: Reaction-driven de novo design of bioactive compounds. PLoS Computational Biology, 8, 2012, e1002380.
54. Hawkins, P.C., Skillman, A.G., Nicholls, A., Comparison of shape-matching and docking as virtual screening tools. Journal of Medicinal Chemistry 50 (2007), 74–82.
55. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nature Biotechnology 32 (2014), 40–51.
56. Heikamp, K., Bajorath, J., The future of virtual compound screening. Chemical Biology & Drug Design 81 (2013), 33–40.
57. Hert, J., Willett, P., Wilton, D.J., Acklin, P., Azzaoui, K., Jacoby, E., Schuffenhauer, A., New methods for ligand-based virtual screening: Use of data fusion and machine learning to enhance the effectiveness of similarity searching. Journal of Chemical Information and Modeling 46 (2006), 462–470.
58. Hevener, K.E., Mehboob, S., Su, P.C., Truong, K., Boci, T., Deng, J.,.. Johnson, M.E., Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. Journal of Medicinal Chemistry 55 (2012), 268–279.
59. Hillisch, A., Hilgenfeld, R., The role of protein 3D structures in the drug discovery process. Hillisch, A., Hilgenfeld, R., (eds.) Modern methods in drug discovery, 2003, Birkhäuser Verlag, 157–182.
60. Hillisch, A., Heinrich, N., Wild, H., Computational chemistry in the pharmaceutical industry: From childhood to adolescence. ChemMedChem 10 (2015), 1958–1962.
61. Hindle, S.A., Rarey, M., Buning, C., Lengauer, T., Flexible docking under pharmacophore type constraints. Journal of Computer-Aided Molecular Design 16 (2002), 129–149.
62. Hol, W.G.J., Protein cristallography and computer-graphics towards rational drug design. Angewandte Chemie (International Ed. in English) 25 (1988), 767–778.
63. Hopkins, A.L., Groom, C.R., The druggable genome. Nature Reviews. Drug Discovery 1 (2002), 727–730.
64. Hopkins, A.L., Groom, C.R., Alex, A., Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 9 (2004), 430–431.
65. Hopkins, A.L., Mason, J.S., Overington, J.P., Can we rationally design promiscuous drugs?. Current Opinion in Structural Biology 16 (2006), 127–136.
66. Horvath, D., Lisurek, M., Rupp, B., Kuhne, R., Specker, E., von Kries, J.,.. Frank, R., Design of a general-purpose European compound screening library for EU-OPENSCREEN. ChemMedChem 9 (2014), 2309–2326.
67. Hou, T., Wang, J., Li, Y., Wang, W., Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information and Modeling 51 (2011), 69–82.
68. Hoveyda, H.R., Marsault, E., Gagnon, R., Mathieu, A.P., Vezina, M., Landry, A.,.. Fraser, G.L., Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (part I): Development of ulimorelin (TZP-101) from hit to clinic. Journal of Medicinal Chemistry 54 (2011), 8305–8320.
69. Huang, T.W., Zaretzki, J., Bergeron, C., Bennett, K.P., Breneman, C.M., DR-predictor: Incorporating flexible docking with specialized electronic reactivity and machine learning techniques to predict CYP-mediated sites of metabolism. Journal of Chemical Information and Modeling 53 (2013), 3352–3366.
70. Hughes, L.D., Palmer, D.S., Nigsch, F., Mitchell, J.B., Why are some properties more difficult to predict than others? A study of QSPR models of solubility, melting point, and log P. Journal of Chemical Information and Modeling 48 (2008), 220–232.
71. Irwin, J.J., Duan, D., Torosyan, H., Doak, A.K., Ziebart, K.T., Sterling, T.,.. Shoichet, B.K., An aggregation advisor for ligand discovery. Journal of Medicinal Chemistry 58 (2015), 7076–7087.
72. Johnson, D.K., Karanicolas, J., Ultra-high-throughput structure-based virtual screening for small-molecule inhibitors of protein-protein interactions. Journal of Chemical Information and Modeling 56 (2016), 399–411.
73. Jordan, M.I., Mitchell, T.M., Machine learning: Trends, perspectives, and prospects. Science 349 (2015), 255–260.
74. Kalaszi, A., Szisz, D., Imre, G., Polgar, T., Screen3D: A novel fully flexible high-throughput shape-similarity search method. Journal of Chemical Information and Modeling 54 (2014), 1036–1049.
75. Kandoi, G., Acencio, M.L., Lemke, N., Prediction of druggable proteins using machine learning and systems biology: A mini-review. Frontiers in Physiology, 6, 2015, 366.
76. Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M., Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Research 42 (2014), D199–D205.
77. Keiser, M.J., Setola, V., Irwin, J.J., Laggner, C., Abbas, A.I., Hufeisen, S.J.,.. Roth, B.L., Predicting new molecular targets for known drugs. Nature 462 (2009), 175–181.
78. Kellenberger, E., Springael, J.Y., Parmentier, M., Hachet-Haas, M., Galzi, J.L., Rognan, D., Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. Journal of Medicinal Chemistry 50 (2007), 1294–1303.
79. Kelley, B.P., Brown, S.P., Warren, G.L., Muchmore, S.W., POSIT: Flexible shape-guided docking for pose prediction. Journal of Chemical Information and Modeling 55 (2015), 1771–1780.
80. Kelly, M.D., Mancera, R.L., Expanded interaction fingerprint method for analyzing ligand binding modes in docking and structure-based drug design. Journal of Chemical Information and Computer Sciences 44 (2004), 1942–1951.
81. Khamis, M.A., Gomaa, W., Ahmed, W.F., Machine learning in computational docking. Artificial Intelligence in Medicine 63 (2015), 135–152.
82. Kier, L.B., Molecular orbital calculation of preferred conformations of acetylcholine, muscarine, and muscarone. Molecular Pharmacology 3 (1967), 487–494.
83. Kilchmann, F., Marcaida, M.J., Kotak, S., Schick, T., Boss, S.D., Awale, M.,.. Reymond, J.L., Discovery of a selective aurora a kinase inhibitor by virtual screening. Journal of Medicinal Chemistry, 2016.
84. Kim, M.T., Sedykh, A., Chakravarti, S.K., Saiakhov, R.D., Zhu, H., Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches. Pharmaceutical Research 31 (2014), 1002–1014.
85. Kirkpatrick, P., An audience with Chris Lipinski. Nature Reviews. Drug Discovery 11 (2012), 900–901.
86. Koes, D.R., Camacho, C.J., PocketQuery: Protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Research 40 (2012), W387–W392.
87. Kolb, P., Rosenbaum, D.M., Irwin, J.J., Fung, J.J., Kobilka, B.K., Shoichet, B.K., Structure-based discovery of beta2-adrenergic receptor ligands. Proceedings of the National Academy of Sciences of the United States of America 106 (2009), 6843–6848.
88. Krasowski, A., Muthas, D., Sarkar, A., Schmitt, S., Brenk, R., DrugPred: A structure-based approach to predict protein druggability developed using an extensive nonredundant data set. Journal of Chemical Information and Modeling 51 (2011), 2829–2842.
89. Krier, M., Bret, G., Rognan, D., Assessing the scaffold diversity of screening libraries. Journal of Chemical Information and Modeling 46 (2006), 512–524.
90. Kruger, D.M., Evers, A., Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors. ChemMedChem 5 (2010), 148–158.
91. Kuang, Q., Purhonen, P., Hebert, H., Structure of potassium channels. Cellular and Molecular Life Sciences 72 (2015), 3677–3693.
92. Kubinyi, H., Sucess stories of computer-aided design. Ekins, S., (eds.) Computer applications in pharmaceutical research and development, 2006, John Wiley & Sons, Inc., 377–424.
93. Kuenemann, M.A., Bourbon, L.M., Labbe, C.M., Villoutreix, B.O., Sperandio, O., Which three-dimensional characteristics make efficient inhibitors of protein-protein interactions?. Journal of Chemical Information and Modeling 54 (2014), 3067–3079.
94. Kufareva, I., Ilatovskiy, A.V., Abagyan, R., Pocketome: An encyclopedia of small-molecule binding sites in 4D. Nucleic Acids Research 40 (2012), D535–D540.
95. Kuhn, B., Gerber, P., Schulz-Gasch, T., Stahl, M., Validation and use of the MM-PBSA approach for drug discovery. Journal of Medicinal Chemistry 48 (2005), 4040–4048.
96. Kuhn, M., Letunic, I., Jensen, L.J., Bork, P., The SIDER database of drugs and side effects. Nucleic Acids Research 44 (2016), D1075–D1079.
97. Kumar, A., Zhang, K.Y., Application of shape similarity in pose selection and virtual screening in CSARdock2014 exercise. Journal of Chemical Information and Modeling, 2015.
98. Laggner, C., Kokel, D., Setola, V., Tolia, A., Lin, H., Irwin, J.J.,.. Shoichet, B.K., Chemical informatics and target identification in a zebrafish phenotypic screen. Nature Chemical Biology 8 (2012), 144–146.
99. Lanevskij, K., Japertas, P., Didziapetris, R., Improving the prediction of drug disposition in the brain. Expert Opinion on Drug Metabolism & Toxicology 9 (2013), 473–486.
100. Langridge, R., Ferrin, T.E., Kuntz, I.D., Connolly, M.L., Real-time color graphics in studies of molecular interactions. Science 211 (1981), 661–666.
101. Larregieu, C.A., Benet, L.Z., Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. The AAPS Journal 15 (2013), 483–497.
102. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y.,.. Wishart, D.S., DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids Research 42 (2014), D1091–D1097.
103. Leach, A.R., Gillet, V.J., Lewis, R.A., Taylor, R., Three-dimensional pharmacophore methods in drug discovery. Journal of Medicinal Chemistry 53 (2010), 539–558.
104. Lei, Q., Liu, H., Peng, Y., Xiao, P., In silico target fishing and pharmacological profiling for the isoquinoline alkaloids of Macleayacordata (Bo Luo Hui). Chinese Medicine, 10, 2015, 37.
105. Li, Q., Lai, L., Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics, 8, 2007, 353.
106. Li, Y.Y., An, J., Jones, S.J., A computational approach to finding novel targets for existing drugs. PLoS Computational Biology, 7, 2011, e1002139.
107. Li, Y., Han, L., Liu, Z., Wang, R., Comparative assessment of scoring functions on an updated benchmark: 2. Evaluation methods and general results. Journal of Chemical Information and Modeling 54 (2014), 1717–1736.
108. Li, H., Leung, K.S., Wong, M.H., Ballester, P.J., USR-VS: A web server for large-scale prospective virtual screening using ultrafast shape recognition techniques. Nucleic Acids Research 44 (2016), W436–W441.
109. Li, L., Wang, B., Meroueh, S.O., Support vector regression scoring of receptor-ligand complexes for rank-ordering and virtual screening of chemical libraries. Journal of Chemical Information and Modeling 51 (2011), 2132–2138.
110. Liu, C., Wrobleski, S.T., Lin, J., Ahmed, G., Metzger, A., Wityak, J.,.. Leftheris, K., 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase. Journal of Medicinal Chemistry 48 (2005), 6261–6270.
111. Loughney, D., Claus, B.L., Johnson, S.R., To measure is to know: An approach to CADD performance metrics. Drug Discovery Today 16 (2011), 548–554.
112. Lounkine, E., Keiser, M.J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J.L.,.. Urban, L., Large-scale prediction and testing of drug activity on side-effect targets. Nature 486 (2012), 361–367.
113. Loving, K.A., Lin, A., Cheng, A.C., Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility. PLoS Computational Biology, 10, 2014, e1003741.
114. Maggiora, G.M., On outliers and activity cliffs–why QSAR often disappoints. Journal of Chemical Information and Modeling, 46, 2006, 1535.
115. Marcou, G., Rognan, D., Optimizing fragment and scaffold docking by use of molecular interaction fingerprints. Journal of Chemical Information and Modeling 47 (2007), 195–207.
116. Martin, Y.C., Kofron, J.L., Traphagen, L.M., Do structurally similar molecules have similar biological activity?. Journal of Medicinal Chemistry 45 (2002), 4350–4358.
117. Mason, J.S., Morize, I., Menard, P.R., Cheney, D.L., Hulme, C., Labaudiniere, R.F., New 4-point pharmacophore method for molecular similarity and diversity applications: Overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. Journal of Medicinal Chemistry 42 (1999), 3251–3264.
118. Meslamani, J., Bhajun, R., Martz, F., Rognan, D., Computational profiling of bioactive compounds using a target-dependent composite workflow. Journal of Chemical Information and Modeling 53 (2013), 2322–2333.
119. Meslamani, J., Li, J., Sutter, J., Stevens, A., Bertrand, H.O., Rognan, D., Protein-ligand-based pharmacophores: Generation and utility assessment in computational ligand profiling. Journal of Chemical Information and Modeling 52 (2012), 943–955.
120. Mestres, J., Veeneman, G.H., Identification of “latent hits” in compound screening collections. Journal of Medicinal Chemistry 46 (2003), 3441–3444.
121. Mirza, S.B., Salmas, R.E., Fatmi, M.Q., Durdagi, S., Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study. Journal of Molecular Graphics & Modelling 66 (2016), 99–107.
122. Modi, S., Li, J., Malcomber, S., Moore, C., Scott, A., White, A., Carmichael, P., Integrated in silico approaches for the prediction of Ames test mutagenicity. Journal of Computer-Aided Molecular Design 26 (2012), 1017–1033.
123. Moitessier, N., Englebienne, P., Lee, D., Lawandi, J., Corbeil, C.R., Towards the development of universal, fast and highly accurate docking/scoring methods: A long way to go. British Journal of Pharmacology 153:Suppl. 1 (2008), S7–26.
124. Morphy, R., Selectively nonselective kinase inhibition: Striking the right balance. Journal of Medicinal Chemistry 53 (2010), 1413–1437.
125. Mpamhanga, C.P., Chen, B., McLay, I.M., Willett, P., Knowledge-based interaction fingerprint scoring: A simple method for improving the effectiveness of fast scoring functions. Journal of Chemical Information and Modeling 46 (2006), 686–698.
126. Muegge, I., Zhang, Q., 3D virtual screening of large combinatorial spaces. Methods 71 (2015), 14–20.
127. Muller, P., Lena, G., Boilard, E., Bezzine, S., Lambeau, G., Guichard, G., Rognan, D., In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. Journal of Medicinal Chemistry 49 (2006), 6768–6778.
128. Naderi, M., Alvin, C., Ding, Y., Mukhopadhyay, S., Brylinski, M., A graph-based approach to construct target-focused libraries for virtual screening. Journal of Cheminformatics, 8, 2016, 14.
129. Nicholls, A., McGaughey, G.B., Sheridan, R.P., Good, A.C., Warren, G., Mathieu, M.,.. Kelley, B., Molecular shape and medicinal chemistry: A perspective. Journal of Medicinal Chemistry 53 (2010), 3862–3886.
130. Over, B., Wetzel, S., Grutter, C., Nakai, Y., Renner, S., Rauh, D., Waldmann, H., Natural-product-derived fragments for fragment-based ligand discovery. Nature Chemistry 5 (2012), 21–28.
131. Perez-Nueno, V.I., Souchet, M., Karaboga, A.S., Ritchie, D.W., GESSE: Predicting drug side effects from drug-target relationships. Journal of Chemical Information and Modeling 55 (2015), 1804–1823.
132. Petrone, P.M., Simms, B., Nigsch, F., Lounkine, E., Kutchukian, P., Cornett, A.,.. Glick, M., Rethinking molecular similarity: Comparing compounds on the basis of biological activity. ACS Chemical Biology 7 (2012), 1399–1409.
133. Petrone, P.M., Wassermann, A.M., Lounkine, E., Kutchukian, P., Simms, B., Jenkins, J.,.. Glick, M., Biodiversity of small molecules - A new perspective in screening set selection. Drug Discovery Today, 2013.
134. Polishchuk, P.G., Madzhidov, T.I., Varnek, A., Estimation of the size of drug-like chemical space based on GDB-17 data. Journal of Computer-Aided Molecular Design 27 (2013), 675–679.
135. PubMed, US National Library of medicine. 2016, National Institutes of Health, Bethesda MD, 20894 U.S.A. ( http://www.ncbi.nlm.nih.gov/pubmed, In).
136. Rabal, O., Amr, F.I., Oyarzabal, J., Novel Scaffold FingerPrint (SFP): Applications in scaffold hopping and scaffold-based selection of diverse compounds. Journal of Chemical Information and Modeling 55 (2015), 1–18.
137. Raies, A.B., Bajic, V.B., In silico toxicology: Computational methods for the prediction of chemical toxicity. Wiley Interdisciplinary Reviews: Computational Molecular Science 6 (2016), 147–172.
138. Rask-Andersen, M., Almen, M.S., Schioth, H.B., Trends in the exploitation of novel drug targets. Nature Reviews. Drug Discovery 10 (2011), 579–590.
139. Rask-Andersen, M., Masuram, S., Schioth, H.B., The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annual Review of Pharmacology and Toxicology 54 (2014), 9–26.
140. Reker, D., Perna, A.M., Rodrigues, T., Schneider, P., Reutlinger, M., Monch, B.,.. Schneider, G., Revealing the macromolecular targets of complex natural products. Nature Chemistry 6 (2014), 1072–1078.
141. Reymond, J.L., The chemical space project. Accounts of Chemical Research 48 (2015), 722–730.
142. Ripphausen, P., Stumpfe, D., Bajorath, J., Analysis of structure-based virtual screening studies and characterization of identified active compounds. Future Medicinal Chemistry 4 (2012), 603–613.
143. Roche, O., Schneider, P., Zuegge, J., Guba, W., Kansy, M., Alanine, A.,.. Schneider, G., Development of a virtual screening method for identification of “frequent hitters” in compound libraries. Journal of Medicinal Chemistry 45 (2002), 137–142.
144. Rogers, D., Hahn, M., Extended-connectivity fingerprints. Journal of Chemical Information and Modeling 50 (2010), 742–754.
145. Rognan, D., Structure-based approaches to target fishing and ligand profile. Molecular Informatics 29 (2010), 167–187.
146. Rognan, D., Proteome-scale docking: Myth and reality. Drug Discovery Today: Technologies 10 (2013), e403–e409.
147. Rognan, D., Towards the next generation of computational chemogenomics tools. Molecular Informatics 32 (2013), 1029–1034.
148. Rollinger, J.M., Schuster, D., Danzl, B., Schwaiger, S., Markt, P., Schmidtke, M.,.. Stuppner, H., In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Medica 75 (2009), 195–204.
149. Roy, A., Skolnick, J., LIGSIFT: An open-source tool for ligand structural alignment and virtual screening. Bioinformatics 31 (2015), 539–544.
150. Ruddigkeit, L., van Deursen, R., Blum, L.C., Reymond, J.L., Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. Journal of Chemical Information and Modeling 52 (2012), 2864–2875.
151. Rydberg, P., Gloriam, D.E., Olsen, L., The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics 26 (2010), 2988–2989.
152. Samuel, A.L., Some studies in machine learning using the game of checkers. IBM Journal of Research and Development 3 (1959), 210–229.
153. Schmidtke, P., Barril, X., Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. Journal of Medicinal Chemistry 53 (2010), 5858–5867.
154. Schneider, P., Schneider, G., De novo design at the edge of chaos. Journal of Medicinal Chemistry 59 (2016), 4077–4086.
155. Schnur, D.M., Hermsmeier, M.A., Tebben, A.J., Are target-family-privileged substructures truly privileged?. Journal of Medicinal Chemistry 49 (2006), 2000–2009.
156. Scior, T., Bender, A., Tresadern, G., Medina-Franco, J.L., Martinez-Mayorga, K., Langer, T.,.. Agrafiotis, D.K., Recognizing pitfalls in virtual screening: A critical review. Journal of Chemical Information and Modeling 52 (2012), 867–881.
157. Seddon, G., Lounnas, V., McGuire, R., van den Bergh, T., Bywater, R.P., Oliveira, L., Vriend, G., Drug design for ever, from hype to hope. Journal of Computer-Aided Molecular Design 26 (2012), 137–150.
158. Segall, M., Advances in multiparameter optimization methods for de novo drug design. Expert Opinion on Drug Discovery 9 (2014), 803–817.
159. Shaked, I., Oberhardt, M.A., Atias, N., Sharan, R., Ruppin, E., Metabolic network prediction of drug side effects. Cell Systems 2 (2016), 209–213.
160. Sheridan, R.P., Maiorov, V.N., Holloway, M.K., Cornell, W.D., Gao, Y.D., Drug-like density: A method of quantifying the “bindability” of a protein target based on a very large set of pockets and drug-like ligands from The Protein Data Bank. Journal of Chemical Information and Modeling 50 (2010), 2029–2040.
161. Simon, Z., Peragovics, A., Vigh-Smeller, M., Csukly, G., Tombor, L., Yang, Z.,.. Malnasi-Csizmadia, A., Drug effect prediction by polypharmacology-based interaction profiling. Journal of Chemical Information and Modeling 52 (2012), 134–145.
162. Sjogren, E., Thorn, H., Tannergren, C., In silico modeling of gastrointestinal drug absorption: Predictive performance of three physiologically based absorption models. Molecular Pharmaceutics 13 (2016), 1763–1778.
163. Sliwoski, G., Kothiwale, S., Meiler, J., Lowe, E.W. Jr., Computational methods in drug discovery. Pharmacological Reviews 66 (2014), 334–395.
164. Spyrakis, F., Cavasotto, C.N., Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description. Archives of Biochemistry and Biophysics 583 (2015), 105–119.
165. Sterling, T., Irwin, J.J., ZINC 15—Ligand discovery for everyone. Journal of Chemical Information and Modeling 55 (2015), 2324–2337.
166. Surgand, J.S., Rodrigo, J., Kellenberger, E., Rognan, D., A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62 (2006), 509–538.
167. Todeschini, R., Consonni, V., Handbook of molecular descriptors. 2000, Wiley-VCH.
168. Todeschini, R., Consonni, V., Xiang, H., Holliday, J., Buscema, M., Willett, P., Similarity coefficients for binary chemoinformatics data: Overview and extended comparison using simulated and real data sets. Journal of Chemical Information and Modeling 52 (2012), 2884–2901.
169. Turner, S.R., Strohbach, J.W., Tommasi, R.A., Aristoff, P.A., Johnson, P.D., Skulnick, H.I.,.. Thaisrivongs, S., Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Journal of Medicinal Chemistry 41 (1998), 3467–3476.
170. van de Waterbeemd, H., Gifford, E., ADMET in silico modelling: Towards prediction paradise?. Nature Reviews. Drug Discovery 2 (2003), 192–204.
171. van Westen, G.J.P., Wegner, J.K., Ijzerman, A.P., van Vlijmen, H.W.T., Bender, A., Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. Medicinal Chemistry Communications 2 (2011), 16–30.
172. Varin, T., Didiot, M.C., Parker, C.N., Schuffenhauer, A., Latent hit series hidden in high-throughput screening data. Journal of Medicinal Chemistry 55 (2012), 1161–1170.
173. Venhorst, J., Nunez, S., Terpstra, J.W., Kruse, C.G., Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. Journal of Medicinal Chemistry 51 (2008), 3222–3229.
174. Verdine, G.L., Hilinski, G.J., Stapled peptides for intracellular drug targets. Methods in Enzymology 503 (2012), 3–33.
175. Vidal, D., Garcia-Serna, R., Mestres, J., Ligand-based approaches to in silico pharmacology. Bajorath, J., (eds.) Chemoinformatics and computational chemical biology, 2011, Humana Press, Totowa, NJ, 489–502.
176. Villoutreix, B.O., Lagorce, D., Labbe, C.M., Sperandio, O., Miteva, M.A., One hundred thousand mouse clicks down the road: Selected online resources supporting drug discovery collected over a decade. Drug Discovery Today 18 (2013), 1081–1089.
177. Vinkers, H.M., de Jonge, M.R., Daeyaert, F.F., Heeres, J., Koymans, L.M., van Lenthe, J.H.,.. Janssen, P.A., SYNOPSIS: SYNthesize and OPtimize system in silico. Journal of Medicinal Chemistry 46 (2003), 2765–2773.
178. Virtanen, S.I., Niinivehmas, S.P., Pentikainen, O.T., Case-specific performance of MM-PBSA, MM-GBSA, and SIE in virtual screening. Journal of Molecular Graphics & Modelling 62 (2015), 303–318.
179. Volkamer, A., Kuhn, D., Grombacher, T., Rippmann, F., Rarey, M., Combining global and local measures for structure-based druggability predictions. Journal of Chemical Information and Modeling 52 (2012), 360–372.
180. von Itzstein, M., Wu, W.Y., Kok, G.B., Pegg, M.S., Dyason, J.C., Jin, B., Van Phan, T., Smythe, M.L., White, H.F., Oliver, S.W., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993), 418–423.
181. Wang, F., Liu, D., Wang, H., Luo, C., Zheng, M., Liu, H.,.. Jiang, H., Computational screening for active compounds targeting protein sequences: Methodology and experimental validation. Journal of Chemical Information and Modeling 51 (2011), 2821–2828.
182. Wang, Y., Xing, J., Xu, Y., Zhou, N., Peng, J., Xiong, Z.,.. Jiang, H., In silico ADME/T modelling for rational drug design. Quarterly Reviews of Biophysics 48 (2015), 488–515.
183. Wassermann, A.M., Lounkine, E., Hoepfner, D., Le Goff, G., King, F.J., Studer, C.,.. Glick, M., Dark chemical matter as a promising starting point for drug lead discovery. Nature Chemical Biology 11 (2015), 958–966.
184. Weisberg, E., Manley, P.W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S.W., Ray, A.,.. Griffin, J.D., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005), 129–141.
185. Wermuth, C.G., Ganellin, C.R., Lindberg, P., Mitscher, L.A., Glossary of terms used in medicinal chemistry (IUPAC recomendations 1998). Pure and Applied Chemistry 70 (1998), 1129–1143.
186. Westermaier, Y., Barril, X., Scapozza, L., Virtual screening: An in silico tool for interlacing the chemical universe with the proteome. Methods 71 (2015), 44–57.
187. Willett, P., Similarity searching using 2D structural fingerprints. Methods in Molecular Biology 672 (2011), 133–158.
188. Wood, J.M., Maibaum, J., Rahuel, J., Grutter, M.G., Cohen, N.C., Rasetti, V.,.. Bedigian, M.P., Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemical and Biophysical Research Communications 308 (2003), 698–705.
189. Xie, L., Bourne, P.E., Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proceedings of the National Academy of Sciences of the United States of America 105 (2008), 5441–5446.
190. Yang, L., Chen, J., He, L., Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Computational Biology, 5, 2009, e1000441.
191. Yang, L., Wang, K., Chen, J., Jegga, A.G., Luo, H., Shi, L.,.. He, L., Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome—clozapine-induced agranulocytosis as a case study. PLoS Computational Biology, 7, 2011, e1002016.
192. Yao, L., Rzhetsky, A., Quantitative systems-level determinants of human genes targeted by successful drugs. Genome Research 18 (2008), 206–213.
193. Yera, E.R., Cleves, A.E., Jain, A.N., Chemical structural novelty: On-targets and off-targets. Journal of Medicinal Chemistry 54 (2011), 6771–6785.
194. Yildirim, M.A., Goh, K.I., Cusick, M.E., Barabasi, A.L., Vidal, M., Drug-target network. Nature Biotechnology 25 (2007), 1119–1126.
195. Zeniou, M., Feve, M., Mameri, S., Dong, J., Salome, C., Chen, W.,.. Kilhoffer, M.C., Chemical library screening and structure-function relationship studies identify bisacodyl as a potent and selective cytotoxic agent towards quiescent human glioblastoma tumor stem-like cells. PloS One, 10, 2015, e0134793.
196. Zhu, T., Cao, S., Su, P.C., Patel, R., Shah, D., Chokshi, H.B.,.. Hevener, K.E., Hit identification and optimization in virtual screening: Practical recommendations based on a critical literature analysis. Journal of Medicinal Chemistry 56 (2013), 6560–6572.
197. Zilian, D., Sotriffer, C.A., SFCscore(RF): A random forest-based scoring function for improved affinity prediction of protein-ligand complexes. Journal of Chemical Information and Modeling 53 (2013), 1923–1933.